---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-025162"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:24:44.884788+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma receives Nasdaq delisting notice for low bid price

## Summary
- Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.
- Company has 180 calendar days until May 19, 2026 to regain compliance by closing at $1 for at least 10 consecutive business days.
- If not cured, may qualify for additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to reverse split.
- Company says it will monitor bid price and assess options; no assurance compliance will be regained.

## SEC filing metadata
- accession: 0001493152-25-025162
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315225025162/0001493152-25-025162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315225025162/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-025162
- JSON: https://secwatch.observer/filing/0001493152-25-025162.json
- Plain text: https://secwatch.observer/filing/0001493152-25-025162.txt

## Key facts
- Listing & Compliance Notices
  GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its common stock, $0.001 par value per share (the “Common Stock”) had closed below $1 per share for 30 consecutive business days and, as a result, the Company was not in compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). This Letter has no immed
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315225025162/0001493152-25-025162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.